Last week Genmab A/S (OTCPK:GNMSF), (OTCPK:GMXAY) announced positive topline results for its phase III ALCYONE study, sponsored by Janssen, a division of Johnson & Johnson (JNJ). ALCYONE studied a front-line, Darzalex-based combination for multiple myeloma.

This was a Revlimid-free combination. And just when it looked like Darzalex combined with Revlimid and dexamethasone might become the combination of choice based on the POLLUX trial.

If Darzalex daratumumab is approved in combination with bortezomib, melphalan, and prednisone as front line, it will be a direct threat to Revlimid maker Celgene (CELG). In the most recent quarter, the $460-a-pill Revlimid accounted for $2,034 of $3,256 (millions) total revenue. Even a modest encroachment by Darzalex will be very costly to Celgene given that degree of dependency on Revlimid.

READ FULL ARTICLE HERE